Standard Biotools (LAB) EBT (2010 - 2026)

Standard Biotools (LAB) has 17 years of EBT data on file, last reported at -$14.6 million in Q1 2026.

• On a quarterly basis, EBT rose 37.78% year-over-year to -$14.6 million in Q1 2026; TTM through Mar 2026 was -$59.7 million, a 89.7% decrease from a year earlier, with the FY2025 full-year figure at -$68.5 million, down 182.61% from the prior year.
• EBT for Q1 2026 stood at -$14.6 million, down from $6.1 million in the prior quarter.
• Over the last five years, EBT for LAB reached as high as $153.3 million in Q4 2022 and fell as low as -$76.9 million in Q1 2022.
• Historically, EBT has averaged -$10.7 million across 5 years, with a median of -$20.9 million in 2023.
• Across the five-year window, EBT tumbled 275.08% in 2022 and soared 186.91% in 2024, its largest moves.
• Year by year, EBT stood at $153.3 million in 2022, then plunged by 91.07% to $13.7 million in 2023, then surged by 186.91% to $39.2 million in 2024, then tumbled by 84.36% to $6.1 million in 2025, then sank by 338.07% to -$14.6 million in 2026.
• Per Business Quant data, the three most recent EBT figures were -$14.6 million in Q1 2026, $6.1 million in Q4 2025, and -$32.9 million in Q3 2025.